Genta Inc. (GNTA.OB) Updates on Melanoma drug Genasense® Phase 3 Trial
As with any small cap research company, the promise is strong but the research time can be long. Therefore updates on how the research is going are necessary so that stockholders and the investment community don't forget that the company has promise and is working on something important. Yesterday, Genta Inc. (OTCBB:GNTA) did just that. It announced its progress on the clinical trials of its promising melanoma drug, Genasense®. This drug may also have broader applications in other cancers as well, since “Genasense® inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis…